Key facts
- This page summarizes Sumitomo Chemical Co., Ltd.'s Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jun 2023, 16:05.
Sumitomo Chemical Co., Ltd. - 22 Jun 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ROIV
- Reported as of
- 22 Jun 2023
- Net transaction value
- -$129,999,982
- SEC form
- 4
- Accepted by SEC
- 26 Jun 2023, 16:05:29 UTC
- Prior SEC filing
- 10 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- Sumitomo Pharma Co., Ltd., By: /s/ Yutaka Wakemi, Name: Yutaka Wakemi, Title: Senior Director, Global Strategy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sumitomo Chemical Co., Ltd. filed Form 4 for Roivant Sciences Ltd. (ROIV) on 26 Jun 2023.
Change
- Previous filing in this sequence was filed on 10 Mar 2023.
- Current net transaction value: -$129,999,982.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Sale
- Transaction value
- $129,999,982
- Shares
- -15,116,277
- Change %
- -18%
- Price
- $8.60
- Shares after
- 71,251,083
- Date
- 22 Jun 2023
- Ownership
- See footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Sumitomo Chemical Co., Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024.
Footnote F2
Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.
SEC remarks
Exhibit 24.1 - Power of Attorney (Sumitomo)